Characterization of Th17 responses to Streptococcus pneumoniae in humans: Comparisons between adults and children in a developed and a developing country

Vaccine

Volumn 30, Issue 26, 2012, Pages 3897-3907

  Lundgren, Anna ^a   Bhuiyan, Taufiqur R ^b   Novak, Daniel ^a,c   Kaim, Joanna ^a   Reske, Adi ^d   Lu, Ying Jie ^d   Qadri, Firdausi ^b   Malley, Richard ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Developing country; IL 17A; Streptococcus pneumoniae; T cell

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; BANGLADESH; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CELL SEPARATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SWEDEN; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ADULT; ANIMALS; ANTIGENS, BACTERIAL; BANGLADESH; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; INFANT; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; SWEDEN; TH17 CELLS;

EID: 84861190678     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.082     Document Type: Article

References (53)

1. Johnson H.L., Deloria-Knoll M., Levine O.S., Stoszek S.K., Freimanis Hance L., Reithinger R., et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Medicine 2010, 7(10).
2. Austrian R. Some aspects of the pneumococcal carrier state. Journal of Antimicrobial Chemotherapy 1986, 18(Suppl. A):35-45.
3. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
4. Plotkin S.A., Orenstein W., Offit PA Vaccines 2008, Saunders. 5th ed.
5. Granat S.M., Mia Z., Ollgren J., Herva E., Das M., Piirainen L., et al. Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh. Pediatric Infectious Disease Journal 2007, 26(4):319-324.
6. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011.
7. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Review of Vaccines 2011, 10(2):187-199.
8. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Current Opinion in Immunology 2011, 23(3):407-413.
9. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proceedings of National Academy of Sciences of the United States of America 2005, 102(13):4848-4853.
10. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infection and Immunity 2001, 69(8):4870-4873.
11. Lu Y.J., Yadav P., Clements J.D., Forte S., Srivastava A., Thompson C.M., et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clinical and Vaccine Immunology 2010, 17(6):1005-1012.
12. Lu Y.J., Leite L., Goncalves V.M., Dias Wde O., Liberman C., Fratelli F., et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28(47):7468-7475.
13. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathogens 2008, 4(9):e1000159.
14. Basset A., Thompson C.M., Hollingshead S.K., Briles D.E., Ades E.W., Lipsitch M., et al. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infection and Immunity 2007, 75(11):5460-5464.
15. Granat S.M., Ollgren J., Herva E., Mia Z., Auranen K., Makela P.H. Epidemiological evidence for serotype-independent acquired immunity to pneumococcal carriage. Journal of Infectious Diseases 2009, 200(1):99-106.
16. Gross J.E., Lu Y.J., Forte S., Tekwe C., Sethis S., Murphy T.F., et al. IL-22 predicts resistance to bacterial colonization in adults with chronic obstructive pulmonary disease. International symposium on pneumococci and pneumococcal diseases 2010.
17. Aniansson G., Alm B., Andersson B., Larsson P., Nylen O., Peterson H., et al. Nasopharyngeal colonization during the first year of life. Journal of Infectious Diseases 1992, 165(Suppl. 1):S38-S42.
18. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 1999, 354(1384):777-785.
19. Leino T., Auranen K., Jokinen J., Leinonen M., Tervonen P., Takala A.K. Pneumococcal carriage in children during their first two years: important role of family exposure. Pediatric Infectious Disease Journal 2001, 20(11):1022-1027.
20. Montgomery J.M., Lehmann D., Smith T., Michael A., Joseph B., Lupiwa T., et al. Bacterial colonization of the upper respiratory tract and its association with acute lower respiratory tract infections in Highland children of Papua New Guinea. Reviews of Infectious Diseases 1990, 12(Suppl. 8):S1006-S1016.
21. Woolfson A., Huebner R., Wasas A., Chola S., Godfrey-Faussett P., Klugman K. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bulletin of the World Health Organization 1997, 75(5):453-462.
22. Lloyd-Evans N., O'Dempsey T.J., Baldeh I., Secka O., Demba E., Todd J.E., et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatric Infectious Disease Journal 1996, 15(10):866-871.
23. Dowell S.F., Garman R.L., Liu G., Levine O.S., Yang Y.H. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clinical Infectious Diseases 2001, 32(5):824-825.
24. Bhuiyan T.R., Qadri F., Janzon A., Chowdhury M.I., Lundin S.B., Lundgren A. Th17 and Th1 responses to Helicobacter pylori in Bangladeshi children and adults. 9th International Workshop on Pathogenesis and Host Response in Helicobacter Infections 2010.
25. Srivastava A., Casey H., Johnson N., Levy O., Malley R. Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease. Infection and Immunity 2007, 75(1):342-349.
26. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000, 18(16):1707-1711.
27. Giefing C., Meinke A.L., Hanner M., Henics T., Bui M.D., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. Journal of Experimental Medicine 2008, 205(1):117-131.
28. Scriba T.J., Kalsdorf B., Abrahams D.A., Isaacs F., Hofmeister J., Black G., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. Journal of Immunology 2008, 180(3):1962-1970.
29. Smith S.G., Lalor M.K., Gorak-Stolinska P., Blitz R., Beveridge N.E., Worth A., et al. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunology 2010, 11:35.
30. Flannery B., Whitney C.G. Uncovering pneumococcal disease burden in Bangladesh. American Journal of Tropical Medicine and Hygiene 2007, 77(5):793-794.
31. Brooks W.A., Breiman R.F., Goswami D., Hossain A., Alam K., Saha S.K., et al. Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. American Journal of Tropical Medicine and Hygiene 2007, 77(5):795-801.
32. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. Journal of Molecular Medicine 2010, 88(2):135-142.
33. Lipsitch M., Whitney C.G., Zell E., Kaijalainen T., Dagan R., Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS Medicine 2005, 2(1):e15.
34. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. Journal of Clinical Investigation 2009, 119(7):1899-1909.
35. Trzcinski K., Thompson C., Malley R., Lipsitch M. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infection and Immunity 2005, 73(10):7043-7046.
36. Moffitt K.L., Gierahn T.M., Lu Y.J., Gouveia P., Alderson M., Flechtner J.B., et al. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9(2):158-165.
37. Malley R., Srivastava A., Lipsitch M., Thompson C.M., Watkins C., Tzianabos A., et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infection and Immunity 2006, 74(4):2187-2195.
38. Schmid P., Selak S., Keller M., Luhan B., Magyarics Z., Seidel S., et al. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 2011, 29(23):3982-3989.
39. Mureithi M.W., Finn A., Ota M.O., Zhang Q., Davenport V., Mitchell T.J., et al. T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. Journal of Infectious Diseases 2009, 200(5):783-793.
40. Sharma S.K., Casey J.R., Pichichero M.E. Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. Journal of Infectious Diseases 2011, 204(4):645-653.
41. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proceedings of National Academy of Sciences of the United States of America 2003, 100(4):1966-1971.
42. Zhang Q., Bagrade L., Bernatoniene J., Clarke E., Paton J.C., Mitchell T.J., et al. Low CD4T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. Journal of Infectious Diseases 2007, 195(8):1194-1202.
43. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. Journal of Experimental Medicine 2006, 203(10):2271-2279.
44. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunology 2007, 8(9):942-949.
45. Eyerich S., Eyerich K., Cavani A. Schmidt-Weber C. IL-17 and IL-22: siblings, not twins. Trends in Immunology 2010, 31(9):354-361.
46. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nature Immunology 2009, 10(8):857-863.
47. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nature Immunology 2009, 10(8):864-871.
48. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Medicine 2008, 14(3):275-281.
49. Lee H.Y., Andalibi A., Webster P., Moon S.K., Teufert K., Kang S.H., et al. Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infectious Diseases 2004, 4:12.
50. Siegrist C.A. The challenges of vaccine responses in early life: selected examples. Journal of Comparative Pathology 2007, 137(Suppl 1):S4-S9.
51. Vanden Eijnden S., Goriely S., De Wit D., Goldman M., Willems F. Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. European Journal of Immunology 2006, 36(1):21-26.
52. Ben-Smith A., Gorak-Stolinska P., Floyd S., Weir R.E., Lalor M.K., Mvula H., et al. Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus?. BMC Infectious Diseases 2008, 8:139.
53. van de Veerdonk F.L., Gresnigt M.S., Kullberg B.J., van der Meer J.W., Joosten L.A., Netea M.G. Th17 responses and host defense against microorganisms: an overview. BMB Reports 2009, 42(12):776-787.